FDAnews Drug Daily Bulletin

RANBAXY CAN APPEAL AGAINST ATORVASTATIN RULING

Nov. 4, 2005
A A

Ranbaxy Laboratories today said the UK High Court had granted it permission to appeal against October 12 ruling of patent infringement of its cholesterol-lowering drug atorvastatin. The UK High Court had ruled that Ranbaxy's atorvastatin product would infringe Warner Lambert/Pfizer's European patent 247633 in the United Kingdom. Atorvastatin is a cholesterol-lowering drug which is marketed by Pfizer as Lipitor.

Business Standard (http://www.business-standard.com/bsonline/storypage.php?bKeyFlag=BO&autono=12134)